Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial.

Stroke and vascular neurology - 1 Jun 2021

Meng Xia, Wang Anxin, Zhang Guojun, Niu Siying, Li Wei, Han Sifei, Fang Fang, Zhao Xingquan, Dong Kehui, Jin Zening, Zheng Huaguang, Chen Kelin, Li Hao, Yang Chengyuan, Wang Yongjun

Abstract excerpt

BACKGROUND AND PURPOSE: Rapid genotyping is useful for guiding early antiplatelet therapy in patients with high-risk nondisabling ischaemic cerebrovascular events (HR-NICE). Conventional genetic testing methods used in CYP2C19 genotype-guided antiplatelet therapy for patients with HR-NICE did not satisfy the needs of the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE)-2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiplatelet Therapy and Cardiovascular Diseases
Share to Atrial Fibrillation Management and Outcomes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clopidogrel

Share to Cytochrome P-450 CYP2C19

Share to Genotype

Share to Pharmacogenetics and Drug Metabolism

Share to Platelet Aggregation Inhibitors

Share to Point-of-Care Systems

Source

Open in PubMed Open full text

Identifiers

PMID: 33952669
DOI: 10.1136/svn-2021-000874
PMCID: PMC8258065

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial.PMID 33952669Read ↗

Development and Validation of a Rapid Point-of-Care CYP2C19 Genotyping PlatformSemantic proximity Read ↗

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.Semantic proximity Read ↗

Comparative analysis of point-of-care bedside cyp2c19-testing guided anti-platelet therapy versus conventional therapies for cardiovascular diseases: a systematic review and meta-analysis.Semantic proximity Read ↗

Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity.Semantic proximity Read ↗

Point of care CYP2C19 genotyping after percutaneous coronary intervention.Semantic proximity Read ↗

Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.Semantic proximity Read ↗

Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.Semantic proximity Read ↗

Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model.Semantic proximity Read ↗

Antiplatelet therapy guided by CYP2C19 point-of-care pharmacogenetics plus multidimensional treatment decisions.Semantic proximity Read ↗

2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping.Semantic proximity Read ↗

Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Pragmatic Randomized Clinical Trial.Semantic proximity Read ↗

Comparison of Two Point-of-Care CYP2C19 Genotyping Assays for Genotype-Guided Antiplatelet Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.